亞盛醫藥-B(06855.HK)與UNITY Biotechnology合作獲得里程碑付款
格隆匯 12 月 22日丨亞盛醫藥-B(06855.HK)發佈公告,公司全球戰略合作伙伴UNITY Biotechnology(UNITY,NASDAQ: UBX)在研藥物UBX1325治療糖尿病性黃斑水腫(DME)的I期臨牀研究已在美國完成首例患者給藥。UBX1325為亞盛醫藥授權UNITY用於抗衰老領域藥物開發的在研化合物Bcl-xL抑制劑BM-962。
該臨牀進展已觸發此前亞盛醫藥和UNITY達成的許可協議的里程碑付款。根據許可協議條款,亞盛醫藥有權獲得以UNITY普通股形式支付的款項,合計228,310股。UNITY此次開展的臨牀試驗為一項開放的I期臨牀研究,旨在評估UBX1325在晚期DME患者中的安全性、耐受性和藥代動力學。該試驗計劃納入約15名患者,預計在2021年上半年獲得安全性和耐受性數據。據UNITY發佈的公開信息顯示, UBX1325在臨牀前試驗中表現出影響衰老細胞、減少血管滲漏、改善視網膜功能的顯著能力。
亞盛醫藥於2016年與UNITY達成戰略合作,其中包括關於化合物庫的合作協議, UNITY獲授權可對亞盛醫藥的Bcl-2系列化合物進行篩選,以用於在抗衰老領域的開發。UNITY選中BM-962作為用於UBX1325研發的化合物。根據適用協議,亞盛醫藥擁有該化合物的大中華地區權益,未來計劃和UNITY成立合資公司,共同開發中國市場。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.